- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 24.07. | How ICH E6 (R3) is changing clinical trials | ||
| 24.07. | Exploring AI-powered cell simulations and the launch of the world's first virtual lab | ||
| 24.07. | Janssen's Darzalex new indication gains EC approval for SMM | ||
| 23.07. | UK enacts law to decentralise manufacture of personalised treatments | ||
| 23.07. | AstraZeneca announces $50bn US investment plans by 2030 | ||
| 23.07. | Sanofi to acquire Vicebio's share capital for $1.15bn upfront | ||
| 22.07. | J&J seeks FDA approval for icotrokinra to treat psoriasis | ||
| 22.07. | Sarepta halts Elevidys shipments following FDA pressure | ||
| 22.07. | Biogen to invest further $2bn in North Carolina's Research Triangle Park | ||
| 21.07. | Life sciences VC Omega Funds closes $647m funding round | ||
| 21.07. | Sarepta refuses to pull gene therapy despite FDA order | ||
| 21.07. | Five considerations when scaling up mAbs in partnership with a CDMO | ||
| 21.07. | CDMO insights podcast series: Our Experience is Your Strength | Episode #2 Gene Therapy Fill-Finish | ||
| 21.07. | Sanofi concludes Blueprint Medicines acquisition | ||
| 21.07. | Fangzhou and Novo Nordisk link on chronic disease management | ||
| 18.07. | Astellas and KISED link to support Korean pharma startups | ||
| 18.07. | ADCs on the rise: MilliporeSigma, Lonza invest in manufacturing while BioNTech adds CMOs ahead of FDA filing | ||
| 18.07. | FDA approves GSK's prefilled syringe presentation of Shingrix | ||
| 18.07. | Can rare disease research in the US thrive under the new administration? | ||
| 17.07. | Ten years of Rare Pediatric Disease Designation: impact on drug approvals | ||
| 17.07. | Sarepta Therapeutics to cut 500 jobs amid restructuring | ||
| 17.07. | Thermo Fisher acquires Sanofi's steriles manufacturing site in US | ||
| 16.07. | PEPFAR funding protection offers "hope" for people living with HIV | ||
| 16.07. | UK government targets manufacturing as it eyes £41bn life science sector growth | ||
| 16.07. | GSK's Blenrep US comeback hindered by eye safety concerns |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .